Lucrezia Paradisi, Lorenza Trabalzini, Federica Finetti^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082155 - 13 August 2026

Abstract Cytoskeletal reorganization is fundamental to essential cellular processes, including shape maintenance, migration, adhesion cytokinesis, and phagocytosis, and its dysregulation is a hallmark of tumor progression. In cancer cells, altered cytoskeletal dynamics promote invasion and genomic instability resulting from mitotic defects. The actin and microtubule cytoskeletons are highly dynamic polymer networks that organize intracellular architecture, establish polarity, and generate the mechanical forces required for cell division and motility. Their dysregulation disrupts normal cell behavior and facilitates tumor invasion and metastasis. The cytoskeleton therefore represents a key source of potential therapeutic targets for inhibiting metastatic dissemination. This More >

Babu Santha Aswani^1,#, Bethsebie Lalduhsaki Sailo^1,#, Young Yun Jung^2,#, Sosmitha Girisa¹, Mangala Hegde¹, Mohammed S Alqahtani^3,4, Mohamed Abbas⁵, Hassan Ali Almubarak⁶, Anupam Bishayee⁷, Kwang Seok Ahn^2,*, Ajaikumar B. Kunnumakkara^1,*

BIOCELL, Vol.50, No.8, 2026, DOI:10.32604/biocell.2026.073397 - 27 July 2026

Abstract Despite the advancements achieved in chemotherapy, cancer continues to remain a formidable and lethal global threat, ranking as the second leading cause of death worldwide. The development of chemoresistance poses a significant hurdle in cancer treatment. Nonetheless, a therapeutic strategy known as chemosensitization has emerged to counteract cancer cell resistance, wherein the efficacy of one drug is augmented by another. Accumulating evidence suggests that natural products have attracted considerable attention in the cancer therapeutic realm due to their ability to combat multidrug resistance with minimal side effects. Ginsenosides, triterpene saponins extracted from Panax ginseng, have demonstrated… More > Graphic Abstract

Avetis Tsaturyan^1,2, Heghine Hakobyan¹, Kristina Hovsepyan¹, Anna Mkrtchyan^1,2, Tatevik Sargsyan^1,2,*, Raffaele Pastore³, Germano Guerra³, Giovanni N. Roviello^4,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.078405 - 16 June 2026

Abstract Cancer is regarded as one of the leading causes of death worldwide, despite the progress of traditional therapies. Chemotherapy, radiotherapy, and surgery are often accompanied by significant side effects and the development of drug resistance contributes to making the fight against cancer even more challenging, which clearly highlights the urgent need to develop new therapeutic molecular approaches. In this context, natural peptides were introduced into the pharmaceutical market in the last decade and have replenished the ranks of effective anticancer agents due to their structural diversity, biocompatibility, and ability to selectively target tumor cells. Natural… More >

H. Kamlesh¹, E. P. Siva^1,*, P. Bathmanaban², O. D. Makinde³, Dharmendra Tripathi⁴

CMES-Computer Modeling in Engineering & Sciences, Vol.147, No.2, 2026, DOI:10.32604/cmes.2026.081147 - 27 May 2026

Abstract The current study comprehensively investigates Williamson nanofluid flow and transport in an asymmetric porous tapered channel under varying slip conditions, using both analytical and supervised machine learning approaches. This mathematical model integrates thermophoresis, Brownian motion, the Soret and Dufour effects, thermal radiation, and a transverse magnetic field to accurately describe thermosoluble transport phenomena relevant to biomedical contexts. The non-Newtonian Williamson formulation is used to explain how fluids, such as blood, dilute when sheared. Darcy resistance is used to describe porous structures in tissue scaffolds, capillary networks, and dialysis membranes. A perturbation method is used to… More >

Maria Franza, Aurora Melfi, Filippo Acconcia, Alessandra di Masi^*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.076509 - 21 May 2026

Abstract Checkpoint kinase 1 (CHK1), a key regulator of cell cycle checkpoints, plays a central role in the DNA damage response network, serving as a critical mediator that links DNA damage detection to DNA repair mechanisms. In recent years, several other cellular functions of CHK1 have gradually been discovered. As well as monitoring genomic integrity, CHK1 coordinates the timing of DNA replication with the availability of metabolic resources. This prevents unscheduled DNA synthesis from exceeding the cell’s metabolic capacity and causing DNA damage. CHK1 activity also contributes to tumour immune surveillance and the modulation of immune… More >

Wubin Zhao^#, Qi Wang^#, Jun Zhang^*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.076406 - 23 March 2026

Abstract Disulfidptosis is a newly identified form of regulated cell death (RCD) first described in 2023, representing a significant advance in understanding programmed cell death pathways. This unique cell death modality is characterized by abnormal intracellular accumulation of disulfide bonds and disruption of redox homeostasis, leading to cytoskeletal collapse without caspase activation. Disulfidptosis is primarily triggered by glucose deprivation in cells with high expression of solute carrier family 7 member 11 (SLC7A11). Under these conditions, insufficient NADPH supply prevents the effective reduction of accumulated cystine to cysteine, thereby inducing disulfide stress. Distinct from apoptosis, ferroptosis, cuproptosis,… More >

Vincenzo Montanarella¹, Marcelo Guerrero^2,3, David Filho^2,3, Júlia German-Cortés¹, Giacomoluciano Vitelli¹, Magalí Sureda¹, Carlos Pavón Regaña¹, Roser Ferrer^1,4, Simó Schwartz^1,4, Esteban Durán-Lara^2,3, Fernanda Andrade^1,5,*, Diana Rafael^1,6,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074061 - 23 March 2026

Abstract Despite remarkable advances in nanomedicine, localized delivery of advanced cancer therapeutics remains underexploited. Advanced therapies based on biopharmaceuticals, immunotherapy, or gene therapy have revolutionized oncology. Yet, their systemic administration is often associated with limitations such as poor site-specific accumulation, instability, and systemic toxicity. Hydrogels/macrogels offer the ability to encapsulate, protect, and release biomolecules in situ with sustained and stimulus-responsive profiles, addressing key translational gaps. This review provides a focused synthesis of the last five years of hydrogel-based research for cancer therapy, with emphasis on peptides, antibodies, immunotherapeutic agents, and gene delivery systems. We discuss design principles,… More > Graphic Abstract

Abhishikt David Solomon^1,*, Himanshu Kumar Vats^2,#, Shivam Chowdhary^3,#, Supriya Nandlal Kanoujiya⁴, Ajit Prakash⁵, Hina Sultana⁶, Sabyasachi Mohanty⁷, Billy W. Day⁸, Tarun Pant^9,10,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.071632 - 24 February 2026

Abstract Tumor survival, genomic stability, and therapy resistance are dictated by the DNA damage response (DDR). Although poly (ADP-ribose) polymerase (PARP) inhibitors have established the DDR as a therapeutic target, many tumors evade first-generation drugs by rewiring their adaptive repair pathways and imposing microenvironmental constraints. This review synthesizes recent discoveries in key DDR pathways, such as PARP, ataxia telangiectasia and Rad3-related kinase (ATR), ataxia telangiectasia mutated kinase (ATM), checkpoint kinase 1 (CHK1), WEE1 G2 checkpoint kinase (WEE1), and DNA-dependent protein kinase (DNA-PK), and describes the next-generation inhibitors designed to increase selectivity and circumvent resistance. We also… More >

Harpreet Kaur^1,*, Dhrubalochan Rana², Sowvik Bag², Paramjeet Singh³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071209 - 19 January 2026

Abstract The prolonged and intricate history of oncological treatments has transitioned significantly since the introduction of chemotherapy. Substantial therapeutic benefits in cancer therapy have been achieved by the integration of conventional treatments with molecular biosciences and omics technologies. Human epidermal growth factor receptor, hormone receptors, and angiogenesis factors are among the established therapies in tumor reduction and managing side effects. Novel targeted therapies like KRAS G12C, Claudin-18 isoform 2 (CLDN18.2), Trophoblast cell-surface antigen 2 (TROP2), and epigenetic regulators emphasize their promise in advancing precision medicine. However, in many cases, the resistance mechanisms associated with these interventions… More > Graphic Abstract

Theano Makridou¹, Elena Vlastou², Vasilios Kouloulias³, Efstathios P. Efstathopoulos⁴, Kalliopi Platoni^4,*

Oncology Research, Vol.33, No.12, pp. 3611-3632, 2025, DOI:10.32604/or.2025.069101 - 27 November 2025

Abstract Nanomedicine has evolved significantly over the last decades and expanded its applications in pediatric oncology, which represents a special domain with unique patients and distinct requirements. Τhe need for early cancer diagnosis and more effective and targeted therapies aiming to increase the pediatric patients’ survival rates and minimize the treatment-related side effects to survivors is profound. Nanoparticles (NPs) come as a beacon of hope to provide sensitive cancer diagnostic tools and assist contrast agents’ transport to the malignant tumors. Besides, NPs could be designed to deliver targeted drugs and genes to tumors, minimizing the medicine-related… More >